ProCE Banner Activity

New Immunotherapy Paradigms Earlier in NSCLC: What Comes After Progression?

Clinical Thought
With checkpoint inhibitors now moving into both unresectable stage III and first-line metastatic NSCLC, how should we approach managing patients who progress on these agents in earlier disease settings? Read my thoughts on these new clinical challenges.

Released: July 26, 2018

Share

Faculty

Edward B Garon

Edward B Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Faculty Disclosure

Primary Author

Edward B Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has disclosed that he has received funds for research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dynavax, Genentech, Eli Lilly, Merck, Mirati, Novartis, and Pfizer.